Pharmaceutical

Pharmaceutical

Transcenta and EirGenix Collaborate to Advance Integrated Continuous Biomanufacturing Technologies

DRRA19 hours ago01 mins

Shots: EirGenix has entered into a strategic collaboration and non-exclusive licensing agreement with Transcenta for its Highly Intensified Continuous Bioprocessing (HiCB) platform Under the agreement, Transcenta will grant EirGenix a non-exclusive license to its HiCB platform, incl. continuous perfusion & integrated hybrid continuous purification process technologies, as well as documentation, know-how & regulatory support to…

Revamping best-selling drugs to combat patent cliff has limits

DRRA19 hours ago07 mins

Newly improved formulations of best-selling drugs can help to stave off the sales losses associated with the patent cliff to some degree. Image credit: Bahtiar Maulanaa via ShutterStock.com. As the looming patent cliff approaches, some major blockbuster drugs are set to lose their exclusivity, with pharma companies making moves to try and reduce the impact….

Intas partners IntegriMedical for needle-free injections in IVF and gynaecology

DRRA19 hours ago01 mins

Intas partners IntegriMedical for needle-free injections in IVF and gynaecology – Express Pharma Home Latest Updates Intas partners IntegriMedical for needle-free injections in IVF and gynaecology Source link

3 ways Kennedy’s MAHA vision on chronic disease will be tested in 2026

DRRA20 hours ago010 mins

In many ways, it’s been a banner year for chronic disease. America’s enduring ailments became a central theme of the Trump administration, with health secretary Robert F. Kennedy Jr. wielding his influence over the president. Trump created a commission focused on childhood chronic illnesses, which issued two reports on the matter. Statehouses across the country…

Innovent receives NMPA approval for Tabosun colon cancer treatment

DRRA20 hours ago03 mins

MSI-H/dMMR colon cancer comprises 15% of resectable cases and responds poorly to chemotherapy. Credit: NMK-Studio/Shutterstock.com. Innovent Biologics has received China’s National Medical Products Administration (NMPA) approval for the New Drug Application (NDA) for Tabosun (ipilimumab N01 injection), a CTLA-4 monoclonal antibody for colon cancer. The approval covers its use in combination with sintilimab as a…

Pharma Outlook 2026: India’s leap from ‘World’s Pharmacy’ to ‘World’s Innovation Partner’

DRRA21 hours ago01 mins

Pharma Outlook 2026: India’s leap from ‘World’s Pharmacy’ to ‘World’s Innovation Partner’ – Express Pharma Home Latest Updates Pharma Outlook 2026: India’s leap from ‘World’s Pharmacy’ to ‘World’s Innovation Partner’ Source link

CARsgen Reports the NMPA’s Dual IND Application Submission for CT0596 to Initiate P-Ib/II Trials in R/R MM and pPCL

DRRA21 hours ago01 mins

Shots: Chinese NMPA received two IND applications for CT0596 to initiate P-Ib/II trials in r/r multiple myeloma (MM) & primary plasma cell leukemia (pPCL), respectively IIT in China showed favorable efficacy as of Aug 31, 2025, with 6/8 evaluable R/R MM pts achieving PR or better (3 CR/sCR, 1 VGPR, 2 PR) at an mFU…

Pharmaceutical

Harbour BioMed Collaborates with Yantai Lannacheng Biotechnology to Develop Radionuclide Drug Conjugates (RDCs)

DRRA22 hours ago01 mins

Shots: Harbour BioMed has entered into a long-term strategic collaboration with Yantai Lannacheng Biotechnology to jointly advance the development of next-generation RDCs Collaboration will combine Harbour’s fully human antibody discovery capabilities via its Harbour Mice platform with Lannacheng’s radiopharmaceutical R&D & commercialization strengths Harbour Mice platform provides fully human mAbs in both conventional & heavy chain-only…

Pharmaceutical

ABL Bio Secures Upfront Payment and Equity Investment from Lilly to Accelerate Grabody Programs

DRRA23 hours ago01 mins

Shots: ABL Bio has secured a total of $55M, incl. $40M upfront & $15M in equity investment, from Eli Lilly under their ~$2.602B license, research & collaboration agreement Under the deal, ABL Bio & Eli Lilly are jointly advancing multiple therapeutic candidates across diverse modalities, leveraging ABL Bio’s Grabody platform for collaborative research & development…

Akums signs MoU with Sharda University Agra for pharma research and skill development

DRRA23 hours ago01 mins

Akums signs MoU with Sharda University Agra for pharma research and skill development – Express Pharma Home Latest Updates Akums signs MoU with Sharda University Agra for pharma research and skill development …

Lupin signs exclusive agreement with Gan & Lee for Bofanglutide in India

Dr. M’s Women and Children First Podcast #69 Repost – Stephen Porges, Ph.D. – Polyvagal Theory –

My Viral Recipes of 2025

A Poem By Gabriel Mojay

💄🧠 The Psychology of Lipstick — Why Wearing Lip Color Changes How You

When Is Bath & Body Works’ Semi-Annual Sale? Best Deals Here

Transcenta and EirGenix Collaborate to Advance Integrated Continuous Biomanufacturing Technologies

Revamping best-selling drugs to combat patent cliff has limits

Intas partners IntegriMedical for needle-free injections in IVF and gynaecology

3 ways Kennedy’s MAHA vision on chronic disease will be tested in 2026

Innovent receives NMPA approval for Tabosun colon cancer treatment

Pharma Outlook 2026: India’s leap from ‘World’s Pharmacy’ to ‘World’s Innovation Partner’

CARsgen Reports the NMPA’s Dual IND Application Submission for CT0596 to Initiate P-Ib/II Trials in R/R MM and pPCL

Harbour BioMed Collaborates with Yantai Lannacheng Biotechnology to Develop Radionuclide Drug Conjugates (RDCs)

ABL Bio Secures Upfront Payment and Equity Investment from Lilly to Accelerate Grabody Programs

Akums signs MoU with Sharda University Agra for pharma research and skill development